In March 2016 Nicoccino Holding developed a new strategic direction with an increased focus on achieving a drug classification for the company’s alternative nicotine product – NicoccinoTM– in order to position the product as a smoking cessation.
This new direction has resulted in a revised set of strategies as well an amended business model and Vision/Mission for the company that can be seen below.
The strategy is to create a product platform that can be used by partners who wish to establish themselves in the market of Nicotine Replacement Therapy (NRT) or want to expand their existing product portfolio. Sales to consumers will be managed indirectly through a license model with international partners who are more financially equipped to reach out globally. The company is actively also seeking a buyer for the patent or licensing of the patent.
“With a clear classification the regulatory uncertainty will be reduced and new markets will open up that previously were not accessible. We will lower our costs in the Group considerably, which means that we will have no need for additional funding the coming 12 months” says Johan Cram, CEO of Nicoccino Holding AB.
VISION
To offer a unique and attractive nicotine product that is the most effective on the market.
MISSION
Offer consumers a pure nicotine experience and an effective aid to quit smoking.
STRATEGIC GOALS
- Secure a new pharmaceutical manufacturer.
- Carry out test, validation and clinical production.
- Completion of a clinical study.
- Receive a pharmaceutical approval from the Medical Products Agency [MPA].
BUSINESS IDEA
Nicoccino will, through its patented product platform, offer an attractive Nicotine Replacement Therapy which is the most effective on the market.
BUSINESS MODEL
The business model is based on introducing the product platform to international partners that wish to establish themselves in the market of Nicotine Replacement Therapy (NRT) or want to expand their existing product portfolio, launching the product themselves globally or in different regions.
The licensing model could mean that the strategy is adapted to the conditions for each respective geographical market. Partnerships can also be established at earlier stages of the clinical approval process. The Company is also open for sales of patent or licensing of patent.
For more information, visit Nicoccino’s webpage http://nicoccino.se/en or contact:
Johan Cram, CEO
+46 708 980 418
johan.cram@nicoccino.se
About Nicoccino Holding AB
Nicoccino has developed an innovative and patented nicotine product that after completion of a clinical study will be classified as a medicine for smoking cessation (Nicotine Replacement Therapy – NRT). With a clear classification, regulatory uncertainty will be reduced and new markets will open up that previously were not accessible. Sales to consumers will be managed through a license model with international partners who are more financially equipped to reach out globally.
In 2014/2015 a commercial test launch was conducted in the UK where Nicoccino™ was sold as a consumer product online, and in retail. This introduction confirmed that the product works and that there is a great potential for this new type of nicotine product.
In early 2016 a new strategy was formed with an increased focus on creating a product platform that can be used by partners who wish to establish themselves in the market of Nicotine Replacement Therapy (NRT) or want to expand their existing product portfolio. This new strategy has resulted in the prioritization of achieving a drugs classification, which is of importance when entering partnerships.
Nicoccino has its head quarter located in Täby outside of Stockholm. The company’s shares are listed on Nasdaq Stockholm First North since June 2014 and can be found under the abbreviation NICO.
Remium Nordic AB is the Nicoccino’s certified adviser.
Johan Cram
CEO
+46 708-980 418
johan.cram@nicoccino.se
Nicoccino has developed a patented, innovative and discrete strip that through its unique delivery method instantly provides the user with nicotine without the detrimental side effects of smoking.
The product is designed to offer smokers an attractive alternative when they want to quit smoking.
After a pharmaceutical approval, the product will be sold as a smoking cessation drug (Nicotine Replacement Therapy – NRT).
Release